Page 1

Medacta International Press Release - Ad - hoc announcement pursuant to Art . 53 LR ● + Medacta Group SA reports 35.4 % growth at constant currency of half - year revenue and revises upward the revenue target for 2021 1H 2021 revenue increased to Euro 177.5 million , or 35.4 % at constant currency ( 31.7 % reported ) vs 1H 2020 . The growth was driven by significant carry - over and customer acquisition , in addition to faster - than - expected normalization of surgery activities , with positive contributions from all business lines and geographies . Innovation continued with 50+ new products registered , including CE - marking of the Knee , Shoulder and Spine Applications of the NextAR Augmented Reality Surgical Platform . The positive performance and the business outlook allow to revise upward our revenue target for 2021 within a range of Euro 355 million to Euro 375 million at constant currency , compared to the previous range of Euro 333 million to Euro 348 million , subject to any unforeseen events , specifically from the Covid - 19 pandemic . CASTEL SAN PIETRO , 20 July 2021 - Medacta Group SA ( " Medacta " , SIX : MOVE ) announces today first semester 2021 preliminary unaudited revenue . Francesco Siccardi , CEO of Medacta , commented : " I am really satisfied with the revenue performance achieved in the semester that was driven not only by surgery volumes , but also by the execution of our growth strategy , which continued in 2020 despite the challenging conditions , through the launch of new products , the hiring of salesforce and our continuous medical education programs . The positive semester performance and the business outlook in the remainder of the year allow us to revise upward our revenue guidance for 2021 " concluded Francesco Siccardi . In the first semester 2021 innovation continued and over 50 new products across all our business lines were registered , including entry in new geographies . In June 2021 , the first surgeries based on our NextAR Augmented Reality ( AR ) Surgical Platform were performed in Europe , following the CE - marking of the Knee , Shoulder and Spine Applications . Also , in May 2021 , the NextAR Shoulder Application received FDA clearance , further expanding the U.S. NextAR offering , which already included the Knee Application , FDA - cleared in 2020. NextAR enhances our MySolutions Ecosystem , empowering our holistic approach to personalized medicine , and has the potential to improve surgical accuracy . Thanks to its limited upfront capital investment and reduced cost per case compared to other technologies , the platform enhances healthcare system sustainability